Dual Repurposing Strategy: Rivaroxaban and Ciprofloxacin as a Synergistic Anticancer Therapy in Cervical Cancer: Insight into Inhibition of Metastasis via Targeting the EMT Pathway.

ABSTRACT:

Objective

This study assessed the anticancer and antimetastatic impact of rivaroxaban-ciprofloxacin mixture and explored its molecular mechanism by examining its ability to target the epithelial-mesenchymal transition (EMT) pathway.

Methods

Following incubation periods of 24 and 72 hours, HeLa and normal human fibroblast (NHF) cell lines were employed to investigate the anticancer and safety properties of rivaroxaban, ciprofloxacin, rivaroxaban-ciprofloxacin mixture, and carboplatin, with concentrations varying from 0.1 to 1000 µg/ml. The wound healing assay (WHA) of cervical cancer cells was employed to assess the anti-metastatic effects of the mixture at three time points: 0, 12, and 24 hours.. A combination index (CI) and selectivity toxicity index (SI) score were estimat

SUBMITTER: Ahmed AA 

PROVIDER: S-EPMC12948181 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature